Hui Zhang, MD, PhD
she/her/hers
Associate Professor of Genetics; Co-Director, DNA Diagnostic Lab, GeneticsCards
About
Research
Publications
2019
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang R, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer Journal 2019, 9: 95. PMID: 31780660, PMCID: PMC6882812, DOI: 10.1038/s41408-019-0259-8.Commentaries, Editorials and LettersPRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells
Zhu F, Guo H, Bates P, Zhang S, Zhang H, Nomie K, Li Y, Lu L, Seibold K, Wang F, Rumball I, Cameron H, Hoang N, Yang D, Xu W, Zhang L, Wang M, Capitini C, Rui L. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia 2019, 33: 2898-2911. PMID: 31123343, PMCID: PMC7494157, DOI: 10.1038/s41375-019-0489-6.Peer-Reviewed Original ResearchAntineoplastic AgentsGene Expression Regulation, NeoplasticGerminal CenterHumansImmunohistochemistryIsoquinolinesLymphoma, Large B-Cell, DiffuseModels, BiologicalNF-kappa BPhosphatidylinositol 3-KinasesProtein-Arginine N-MethyltransferasesProto-Oncogene Proteins c-aktPyrimidinesReceptors, Antigen, B-CellSignal TransductionPleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
Li C, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Nomie K, Zhang L, Wang M. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Molecular Cancer Therapeutics 2019, 18: molcanther.0478.2018. PMID: 30413649, PMCID: PMC6363842, DOI: 10.1158/1535-7163.mct-18-0478.Peer-Reviewed Original ResearchAgammaglobulinaemia Tyrosine KinaseAnimalsCell Line, TumorCell ProliferationCell SurvivalDrug Resistance, NeoplasmFemaleGene EditingGene Expression Regulation, NeoplasticHumansLymphoma, Mantle-CellMicePiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesSignal TransductionStress, PhysiologicalXenograft Model Antitumor Assays
2018
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma
Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li C, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie K, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 2018, 38: 1802-1814. PMID: 30361685, DOI: 10.1038/s41388-018-0550-3.Peer-Reviewed Original ResearchAdenineAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDrug SynergismHistonesHumansLymphoma, Mantle-CellMaleMiceMorpholinesPhosphoinositide-3 Kinase InhibitorsPiperidinesPyrazolesPyrimidinesSignal TransductionXenograft Model Antitumor AssaysActivation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
Lee J, Zhang L, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang M, Wang Y. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Advances 2018, 2: 2039-2051. PMID: 30115641, PMCID: PMC6113611, DOI: 10.1182/bloodadvances.2018016048.Peer-Reviewed Original ResearchStrategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Pham L, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis R, Young K, Medeiros L, Ford R, Nomie K, Zhang L, Wang M. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clinical Cancer Research 2018, 24: 3967-3980. PMID: 29666304, DOI: 10.1158/1078-0432.ccr-17-3004.Peer-Reviewed Original ResearchAnimalsApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorCell ProliferationDisease Models, AnimalDNA DamageDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMiceNeoplasm ProteinsOncogene Protein v-aktPhosphatidylinositol 3-KinasesProteomicsProto-Oncogene Proteins c-bcl-2SulfonamidesXenograft Model Antitumor AssaysThe CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer Journal 2018, 8: 33. PMID: 29559616, PMCID: PMC5861115, DOI: 10.1038/s41408-018-0066-7.Commentaries, Editorials and Letters
2017
Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy
Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating M, Liu J, McKeehan W, Wang H, Luo Y, Huang P. Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLOS Biology 2017, 15: e1002616. PMID: 29227990, PMCID: PMC5724824, DOI: 10.1371/journal.pbio.1002616.Commentaries, Editorials and LettersStructural optimization elaborates novel potent Akt inhibitors with promising anticancer activity
Liu Y, Yin Y, Zhang Z, Li C, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang M, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. European Journal Of Medicinal Chemistry 2017, 138: 543-551. PMID: 28704757, DOI: 10.1016/j.ejmech.2017.06.067.Peer-Reviewed Original Research
2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
Wang M, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young K, Li S, Santos D, Medeiros L, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet Oncology 2015, 17: 48-56. PMID: 26640039, DOI: 10.1016/s1470-2045(15)00438-6.Peer-Reviewed Original Research
Clinical Care
Overview
Hui Zhang, MD, PhD, is a geneticist who specializes in caring for children born with birth defects or developmental disabilities. She regularly diagnoses children and adults with developmental disabilities, autism spectrum disorders, craniofacial anomalies, inherited eye disorders, hearing loss, and various birth defects.
While Dr. Zhang was completing her doctorate degree, she worked in research labs that looked at genetic causes of human diseases. “It piqued my interest in clinical genetics,” Dr. Zhang says.
At Yale Medicine, Dr. Zhang focuses on identifying the genetic causes for patients' conditions, and helping her patients and their families to understand their conditions. She believes that knowledge of the condition can help significantly, even if a cure doesn’t yet exist.
As a geneticist, Dr. Zhang assists patients with navigating complex medical care that may require visits to different specialists to address various symptoms. “I try to provide comprehensive care for patients with complex medical problems,” Dr. Zhang says. “I help guide them to make sure they get the appropriate care and find the necessary support.”
At Yale School of Medicine, Dr. Zhang is an associate professor of genetics and of pediatrics. She is also co-director of the DNA Diagnostic Lab, which forms diagnostic testing to identify genetic causes of various medical conditions.
Clinical Specialties
Pediatrics; Genetics; Clinical Genetics
Fact Sheets
Angelman Syndrome
Learn More on Yale MedicinePediatric Cancer
Learn More on Yale MedicinePsychological Assessment of Children
Learn More on Yale MedicineChild Development
Learn More on Yale Medicine
Yale Medicine News
News
News
- September 10, 2024
NIH Recognizes Yale’s Expertise in the Genetics of Rare Diseases
- February 06, 2024
The FDA’s Proposed Ruling on Lab Tests Could Have Unintended Consequences
- September 20, 2021
A Day in the Life of a Genetic Counselor in the Yale Genetics Department
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.